Retension Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RTSN | RLMD | RVX.TO | PHAR | BBOT | RZLT | |
|---|---|---|---|---|---|---|
| Market cap | 96.60M | 444.81M | 27.54M | 881.90M | 184.40M | 383.02M |
| P/E (TTM) | — | — | — | 38.9 | — | — |
| Forward P/E | -4.8 | -10.2 | — | 69.2 | -0.8 | -8.5 |
| Price/book | -0.6 | 2.2 | -0.2 | 2.9 | 0.6 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +11.97% | +59.77% | −20.00% | −15.24% | −81.22% | −57.11% |
| Today | −1.65% | −2.34% | +6.67% | −3.63% | −0.86% | −1.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RTSN news ›reAlpha Tech Corp. Announces Pricing of $1.75 Million Public Offering
The Manila Times reAlpha Tech Corp. Announces Pricing of $1.75 Million Public Offering DUBLIN, Ohio, Nov. 03, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (the "Company” or "reAlpha”), an AI-powered real estate tech
Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) Sees Significant Increase in Short Interest
Posted by Danessa Lincoln on Nov 2nd, 2026 Retension Pharmaceuticals, Inc. (NASDAQ:RTSN – Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 62,034 shares. Based on…
Rekor Systems Says Common Stock Continues To Trade On Nasdaq Under Symbol REKR
TradingView Rekor Systems Says Common Stock Continues To Trade On Nasdaq Under Symbol REKR
Aspen Neuroscience Announces Pricing of Initial Public Offering
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today announced the…
Long term debt to total assets ratio of TAHO Pharmaceuticals Ltd – TWSE:6467
Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research &…
Falls Church’s Retension Pharmaceuticals Prices Upsized $45 Million IPO to Advance Hypertension Drug RTN-001
Retension plans to use the net proceeds, together with existing cash, to complete its Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and to prepare for and advance a planned Phase 3 trial, with the remainder going to…
Retension Pharmaceuticals: PVG reports 8.3% stake
Sole voting power covers 1,002,050 shares, while power to dispose of those shares is shared, according to PVG Asset Management's ownership disclosure. - [SCHEDULE 13G] Retension Pharmaceuticals, Inc. Passive Investment Disclosure (>5%)…
Retension Pharmaceuticals CEO holds 7.07% after IPO
Transfers are restricted until 180 days after the prospectus date, with limited exceptions; 255,174 option shares are excluded from beneficial ownership. - [SCHEDULE 13D] Retension Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%)…
Retension Pharmaceuticals: B Group reports 833K shares
B Group Capital LLC directly holds 833,333 shares of Retension Pharmaceuticals (RTSN). Stock Titan - [Form 3] Retension Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership Retension Pharmaceuticals: B Group reports 833K shares…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- tradingview.com13
- stocktitan.net9
- manilatimes.net3
- financialcontent.com2
- pluang.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 43 articles, not a forecast.